SMTISanara MedTech Inc.
Is the business good?
The checks split: nothing decisive, though margins widening.
Operating profit is mostly backed by cash. Conversion is improving vs a year ago.
Positive operating leverage, operating profit is growing faster than sales, so margins widen as the business scales.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is SMTI?
Sanara MedTech Inc. keeps 7.7% of every revenue dollar as operating profit, against 6.9% for the median Medical Instruments & Supplies name.
Operating margin · Medical Instruments & Supplies median 6.9% · 12 months to Q2 2026
- Cash conversion
- 0.86×
Cash conversion · 0.73× a year ago · most of the operating profit arrived as cash, working capital took the rest
- Share count, year on year
- −3.0%
Share count, year on year · bought back, each share owns more of the company
- R&D as % of revenue
- 4.5%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −32% |
| FY2021 | −31% |
| FY2022 | −27% |
| FY2023 | −6.5% |
| FY2024 | 1.5% |
| FY2025 | 7.1% |
Details›
- Gross margin12 months to Q2 2026
- 93%
- Operating margin12 months to Q2 2026
- 7.7%
- Net margin12 months to Q2 2026
- −29%
- Free cash flow margin
- 4.1%
- R&D as % of revenue
- 4.5%
- Revenue, trailing twelve months
- $110M
- Free cash flow, trailing twelve months
- $4.5M
- Net income, trailing twelve months
- −$32M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Medical Instruments & Supplies
Ranks #13 of 20 by RyuScore